FDA Determines Regulatory Review Period for BAYTRIL Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Sandoz's BAYTRIL, a medication for treating animal diseases, in response to a patent extension application submitted to the US Patent and Trademark Office.